An interventional study of Opioid Free Anesthesia and Opioid based anesthesia in Opioid Free Anesthesia, Pectoral Nerve Block and Breast Cancer Surgery, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Tanta University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Breast Neoplasms by Tanta University — 4 open to participants now, 4 under way, 1 of them phase 3. Breast Neoplasms · Tanta University.
Among the 14 studies in Breast Neoplasms by Tanta University, this one is the 5th largest by enrollment, is one of 3 that started in 2025, is one of 2 with no phase, and was the 14th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →4 of the 14 studies in Breast Neoplasms by Tanta University are open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Women only · Healthy volunteers
Tanta University · Sites in Egypt
Ages 18–65 · Women only
Tanta University · Sites in Egypt
Ages 50+ · Women only
Tanta University · Sites in Egypt
Ages 18–65 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 5 · Phase 4 2
First in 2014; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 48 across the 14 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
2 of the studies in Breast Neoplasms by Tanta University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07370506Tanta UniversityTelmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients | 2027-01 |
| NCT07436663Tanta UniversityComparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Breast Neoplasms by Tanta University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate the efficacy of opioid free anesthesia combined with pectoral Nerve Block (PECS block) in patients undergoing breast cancer surgery.
Breast cancer is the most commonly diagnosed neoplasm in women and accounts for nearly a third (29%) of all malignancies, representing the leading cause of cancer death among women worldwide.
Pectoralis Nerve Block (PECS), is an ultrasound-guided regional anesthesia technique used to block the nerves of the chest wall, providing analgesia for breast surgery and other anterior chest wall procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received ultrasound-guided pectoral nerve block (PECS) using 30 mL of 0.25% bupivacaine after induction of anesthesia. General Anesthesia was induced in an opioid-free manner.
Procedure: Opioid Free Anesthesia
Patients received conventional general anesthesia with intraoperative opioids as per institutional protocol.
Procedure: Opioid based anesthesia
Patients received ultrasound-guided pectoral nerve block (PECS) using 30 mL of 0.25% bupivacaine after induction of anesthesia. General Anesthesia was induced in an opioid-free manner.
Patients received conventional general anesthesia with intraoperative opioids as per institutional protocol.
Total morphine consumption
For each patient with \[Visual Analogue Scale (VAS) \> 4\], 3 mg of morphine will be prescribed as rescue analgesia to be repeated after 30 min if pain persists until the VAS\< 4.
Time frame: 24 hours postoperatively
Heart rate
Heart rate was recorded at baseline, after performing of block, and every 15 min till the end of surgery.
Time frame: Till the end of surgery (Up to 2 hours)
Mean arterial blood pressure
Mean arterial blood pressure was recorded at baseline, after performing of block, and every 15 min till the end of surgery.
Time frame: Till the end of surgery (Up to 2 hours)
Degree of pain
All the participants were explained about postoperative pain assessment with the visual analogue scale (VAS), from 0 to 10 (0 represents "no pain" while 10 represents "the worst pain imaginable")
Time frame: 24 hours postoperatively
Time to extubation
The time to extubate was counted starting from stoppage of inhalational anesthetic agent till the extubating was practiced.
Time frame: Till the extubating (Up to 60 minutes)
Quality of recovery
Quality of recovery was assessed using Modified Aldrete Score (depending on conscious level, activity of the patient, breathing, blood pressure, oxygen saturation).
Time frame: 24 hours postoperatively
Time to the 1st rescue analgesia
Time to the first request for the rescue analgesia was recorded from end of surgery to first dose of morphine administrated.
Time frame: 24 hours postoperatively
Incidence of side effects
Incidence of side effects such as bradycardia, hypotension, nausea, vomiting, respiratory depression, hematoma at the site of injection, and local anesthetic toxicity were recorded.
Time frame: 24 hours postoperatively
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Oct 2026, 12 months.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 12 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.